Eribulin mesylate and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Eribulin mesylate (eribulin mesylate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Capecitabine, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Disease progression when taking Eribulin mesylate. It is created by eHealthMe based on reports of 365 people who have side effects when taking Eribulin mesylate from the FDA, and is updated regularly.

What is Eribulin mesylate?

Eribulin mesylate has active ingredients of eribulin mesylate. eHealthMe is studying from 366 Eribulin mesylate users. Check the latest studies of Eribulin mesylate.

What is Disease progression?

Disease progression is found to be associated with 1,802 drugs and 2,253 conditions by eHealthMe. Check the latest studies of Disease progression.

On Jul, 05, 2026

365 people reported to have side effects when taking Eribulin mesylate.
Among them, 33 people (9.04%) have Disease progression.

Could Eribulin mesylate cause Disease progression?

Among these 33 people:

How long have people been on Eribulin mesylate when they have Disease progression? *

What is the gender of people who have Disease progression when taking Eribulin mesylate? *

female: 100 %
male: 0.0 %

What is the age of people who have Disease progression when taking Eribulin mesylate? *

What are other drugs people take besides Eribulin mesylate? *

What are other side effects people have besides Disease progression? *

Fever: 20 people, 60.61%
Neuropathy Peripheral (surface nerve damage): 17 people, 51.52%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 15 people, 45.45%
Hoarseness Or Changing Voice: 14 people, 42.42%
Colitis (inflammation of colon): 14 people, 42.42%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 14 people, 42.42%
Weight Decreased: 14 people, 42.42%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 14 people, 42.42%
Nausea (feeling of having an urge to vomit): 14 people, 42.42%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 14 people, 42.42%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 20 people, 60.61%
Breast Cancer: 12 people, 36.36%
Urticaria Papular (rash of round, red welts on the skin that itch intensely): 10 people, 30.30%
Gastric Ulcer (stomach ulcer): 10 people, 30.30%
Biliary Sepsis: 10 people, 30.30%
Bleeding Disorders: 10 people, 30.30%
Blepharitis (chronic inflammation of the eyelid): 10 people, 30.30%
Cholecystitis Acute (rapid infection of gallbladder): 10 people, 30.30%
Depressed Mood: 10 people, 30.30%
Gastritis (inflammation of stomach): 10 people, 30.30%

* Approximation only. Some reports may have incomplete information.

Do you take Eribulin mesylate and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eribulin mesylate:

Eribulin mesylate (366 reports)

Browse all side effects of Eribulin mesylate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,802 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,253 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eribulin mesylate (the active ingredients of Eribulin mesylate) and Eribulin mesylate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.